Leerink Partners Initiates Coverage on Palvella Therapeutics (NASDAQ:PVLA)

Investment analysts at Leerink Partners started coverage on shares of Palvella Therapeutics (NASDAQ:PVLA – Get Free Report) in a research note issued on Monday, Briefing.com reports. The brokerage set an “outperform” rating and a $228.00 price target on the stock. Leerink Partners‘s price objective points to a potential upside of 49.53% from the stock’s current price.

A number of other research firms have also commented on PVLA. William Blair initiated coverage on Palvella Therapeutics in a report on Friday, October 16th. They issued an “outperform” rating for the company. Raymond James Financial set a $226.00 price target on Palvella Therapeutics in a report on Friday, October 16th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Palvella Therapeutics in a research report on Friday, September 25th. Oppenheimer increased their price objective on Palvella Therapeutics from $210.00 to $232.00 and gave the company an “outperform” rating in a research report on Friday, November 6th. Finally, Truist Financial set a $207.00 price objective on Palvella Therapeutics in a report on Wednesday, August 5th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $214.86.

Read Our Latest Report on Palvella Therapeutics

Palvella Therapeutics Stock Performance

Shares of Palvella Therapeutics stock opened at $152.48 on Monday. Palvella Therapeutics has a 12-month low of $72.22 and a 12-month high of $179.95. The company has a market cap of $2.23 billion, a P/E ratio of -27.72 and a beta of -0.21. The company’s fifty day simple moving average is $143.56 and its two-hundred day simple moving average is $129.97.

Palvella Therapeutics (NASDAQ:PVLA – Get Free Report) last issued its quarterly earnings results on Thursday, November 5th. The company reported ($1.70) earnings per share for the quarter, topping the consensus estimate of ($1.78) by $0.08. Analysts predict that Palvella Therapeutics will post -6.29 EPS for the current fiscal year.

Insiders Place Their Bets

In other Palvella Therapeutics news, COO Kathleen Goin sold 4,313 shares of the company’s stock in a transaction that occurred on Wednesday, October 21st. The stock was sold at an average price of $124.58, for a total value of $537,313.54. Following the completion of the transaction, the chief operating officer directly owned 2,165 shares in the company, valued at $269,715.70. This represents a 66.58% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Jeffrey S. Martini sold 6,250 shares of the company’s stock in a transaction that occurred on Tuesday, November 10th. The stock was sold at an average price of $166.98, for a total value of $1,043,625.00. Following the completion of the transaction, the insider owned 4,266 shares of the company’s stock, valued at $712,336.68. The trade was a 59.43% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 67,306 shares of company stock valued at $9,800,571 in the last 90 days. 17.20% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Palvella Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of PVLA. Marshall Wace LLP increased its holdings in Palvella Therapeutics by 11,463.8% in the 3rd quarter. Marshall Wace LLP now owns 329,799 shares of the company’s stock valued at $45,489,000 after acquiring an additional 326,947 shares during the last quarter. Voya Investment Management LLC lifted its stake in Palvella Therapeutics by 2.8% in the 3rd quarter. Voya Investment Management LLC now owns 5,878 shares of the company’s stock worth $811,000 after purchasing an additional 162 shares in the last quarter. Royce & Associates LP boosted its holdings in shares of Palvella Therapeutics by 24.7% during the 3rd quarter. Royce & Associates LP now owns 50,509 shares of the company’s stock valued at $6,967,000 after purchasing an additional 10,000 shares during the last quarter. ACT Capital Partners L.P. bought a new position in shares of Palvella Therapeutics during the 3rd quarter valued at about $3,103,000. Finally, William Blair Investment Management LLC bought a new position in shares of Palvella Therapeutics during the 3rd quarter valued at about $26,906,000. Institutional investors own 40.11% of the company’s stock.

About Palvella Therapeutics

(Get Free Report)

Palvella Therapeutics is a clinical-stage biopharmaceutical company developing treatments for patients with rare and serious diseases, with a focus on conditions affecting the skin and related tissues. The company is based in Wayne, Pennsylvania. Its pipeline includes QTORIN-based topical drug candidates, which use the company’s platform to deliver medicines locally to affected tissue. Programs are being developed for conditions including microcystic lymphatic malformations and cutaneous venous malformations; these candidates are investigational and have not been established as approved treatments.

Read More

Analyst Recommendations for Palvella Therapeutics (NASDAQ:PVLA)

Receive News & Ratings for Palvella Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palvella Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.